BHVN vs INVA vs INCY vs ABBV

For growth investors, Incyte Corporation (INCY) is the stronger pick with 21.

2% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Biohaven Ltd. (BHVN) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus AbbVie Inc. at 85. 5x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to +18. 2% for Incyte Corporation (INCY). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus BHVN's +33. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Biohaven Ltd. 's 1. 35β — meaning BHVN is approximately 970% more volatile than INVA relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 5% for Biohaven Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Incyte Corporation (INCY) is pulling ahead at 21.

2% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, INCY leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 0% for Biohaven Ltd. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 0. 0% for BHVN. At the gross margin level — before operating expenses — INCY leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 11. 9x forward P/E versus 14. 3x for AbbVie Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BHVN: 118. 7% to $21. 29.

In this comparison, ABBV (3.

2% yield) pays a dividend. BHVN, INVA, INCY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, BHVN: +33. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BHVN is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; INCY is a mid-cap high-growth stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while BHVN, INVA, INCY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.